Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 70

1.

Adjuvant bisphosphonate treatment for breast cancer: why did something so elegant become so complicated?

Clemons M, Russell K, Costa L, Addison CL.

Breast Cancer Res Treat. 2012 Jul;134(2):453-7. doi: 10.1007/s10549-012-2077-6. Epub 2012 May 5. Review.

PMID:
22562125
3.

Adjuvant bisphosphonate treatment for breast cancer: Where are we heading and can the pre-clinical literature help us get there?

Russell K, Clemons M, Costa L, Addison CL.

J Bone Oncol. 2012 May 24;1(1):12-7. doi: 10.1016/j.jbo.2012.04.003. eCollection 2012 Jun. Review.

4.

Bisphosphonates and breast cancer prevention.

Chlebowski RT, Col N.

Anticancer Agents Med Chem. 2012 Feb;12(2):144-50. Review.

PMID:
21864227
5.

Does adjuvant bisphosphonate in early breast cancer modify the natural course of the disease? A meta-analysis of randomized controlled trials.

Mauri D, Valachis A, Polyzos NP, Tsali L, Mavroudis D, Georgoulias V, Casazza G.

J Natl Compr Canc Netw. 2010 Mar;8(3):279-86.

PMID:
20202461
6.

The role of bisphosphonates in breast and prostate cancers.

Brown JE, Neville-Webbe H, Coleman RE.

Endocr Relat Cancer. 2004 Jun;11(2):207-24. Review.

7.

Adjuvant bisphosphonates: a new standard of care?

Gnant M.

Curr Opin Oncol. 2012 Nov;24(6):635-42. doi: 10.1097/CCO.0b013e32835771aa. Review.

PMID:
23042123
8.

Prevention of bone metastases from breast cancer by adjuvant bisphosphonate therapy.

Kohno N, Kokufu I.

Breast Cancer. 2003;10(1):33-7. Review.

PMID:
12525761
9.

Adjuvant bisphosphonate therapy for breast cancer patients: Standard of care or future direction?

Freedman OC, Amir E, Clemons MJ.

Crit Rev Oncol Hematol. 2009 Oct;72(1):56-64. doi: 10.1016/j.critrevonc.2009.03.001. Epub 2009 Mar 23. Review.

PMID:
19307138
10.

Bisphosphonates: ready for use as adjuvant therapy of breast cancer?

Theriault RL.

Curr Opin Obstet Gynecol. 2010 Feb;22(1):61-6. doi: 10.1097/GCO.0b013e328334e43b. Review.

PMID:
19934757
11.

Bisphosphonates in breast cancer: clinical activity and implications of preclinical data.

Aft R.

Clin Adv Hematol Oncol. 2011 Mar;9(3):194-205. Review.

PMID:
21475125
12.

Lack of evidence for fracture prevention in early breast cancer bisphosphonate trials: a meta-analysis.

Valachis A, Polyzos NP, Georgoulias V, Mavroudis D, Mauri D.

Gynecol Oncol. 2010 Apr;117(1):139-45. doi: 10.1016/j.ygyno.2009.12.001. Epub 2010 Jan 12. Review.

PMID:
20061004
13.

Bisphosphonate therapy in metastatic breast cancer.

Blomqvist C, Elomaa I.

Acta Oncol. 1996;35 Suppl 5:81-3. Review.

PMID:
9142974
14.

Should bisphosphonates be utilized in the adjuvant setting for breast cancer?

Lipton A.

Breast Cancer Res Treat. 2010 Aug;122(3):627-36. doi: 10.1007/s10549-010-0935-7. Epub 2010 May 21. Review.

PMID:
20490653
15.

Adjuvant therapy for breast cancer.

[No authors listed]

NIH Consens Statement. 2000 Nov 1-3;17(4):1-35. Review.

PMID:
11512506
16.

Toward new horizons: the future of bisphosphonate therapy.

Lipton A.

Oncologist. 2004;9 Suppl 4:38-47. Review.

17.

Anticancer activity of bisphosphonates in breast cancer.

Gnant M.

Anticancer Agents Med Chem. 2012 Feb;12(2):114-22. Review.

PMID:
21864231
18.
19.

Current and future status of adjuvant therapy for breast cancer.

Coleman RE.

Cancer. 2003 Feb 1;97(3 Suppl):880-6. Review.

20.

Adjuvant bisphosphonate therapy: the future.

Paterson AH.

Semin Oncol. 2001 Aug;28(4 Suppl 11):81-5. Review.

PMID:
11544582

Supplemental Content

Support Center